Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique最新文献_第3页

[Claude-Michel Lalanne (1919-2017)].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2021-01-08 DOI: 10.1016/j.canrad.2020.12.006

J. Lagrange

引用次数: 0

Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy. 非小细胞肺癌患者肺切除术后放疗发生放射性肺炎的预测因素研究。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2020-10-09 DOI: 10.21203/rs.3.rs-88713/v1

Jialin Yu, Chang-lu Wang, Yuan Liu, Jia-ming Wang, C. Lv, Jun Liu, Zhang Qin, X. Fu, Xuwei Cai

{"title":"Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.","authors":"Jialin Yu, Chang-lu Wang, Yuan Liu, Jia-ming Wang, C. Lv, Jun Liu, Zhang Qin, X. Fu, Xuwei Cai","doi":"10.21203/rs.3.rs-88713/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-88713/v1","url":null,"abstract":"PURPOSE\u0000To identify the valuable predictors of grade≥2 radiation pneumonitis (RP) in patient treated with radiotherapy after pneumonectomy for non-small cell lung cancer (NSCLC); and to construct a nomogram predicting the incidence of grade≥2 RP in such patients.\u0000\u0000\u0000PATIENTS AND METHODS\u0000We reviewed 82 patients with NSCLC received radiotherapy after pneumonectomy from 2008 to 2018. The endpoint was grade≥2 RP. Univariate and multivariate regression analysis were conducted to evaluate significant factors of grade≥2 RP. Receiver operating characteristic (ROC) curve was used to establish optimal cutoff values and the nomogram was built to make the predictive model visualized. Descriptive analysis was performed on 5 patients with grade 3 RP.\u0000\u0000\u0000RESULTS\u0000A total of 22(26.8%) patients developed grade 2 RP and 5(6.1%) patients were grade 3 RP. V5, V10, V20, V30, MLD, PTV, and PTV/TLV were associated with the occurrence of grade≥2 RP in univariate analysis, while none of the clinical factors was significant; V5(OR,1.213;95%CI,1.099-1.339; P<0.001) and V20(OR,1.435;95%CI,1.166-1.765; P=0.001) were the independent significant predictors by multivariate analysis and were included in the nomogram. The ROC analysis for the cutoff values for predicting grade≥2 RP were V5>23% (AUC=0.819, sensitivity:0.701, specificity:0.832) and V20>8% (AUC=0.812, sensitivity:0.683, specificity:0.811). Additionally, grade≥3 RP did not occur when V5<30%, V20<13% and MLD<751.2cGy, respectively.\u0000\u0000\u0000CONCLUSIONS\u0000Our study showed that V5 and V20 were independent predictors for grade≥2 RP in NSCLC patients receiving radiotherapy after pneumonectomy. Grade 3 RP did not occur whenV5<30%, V20<13% and MLD<751.2cGy, respectively. In addition, patient underwent right pneumonectomy may have a lower tolerance to radiation compared to left pneumonectomy.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77014012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

[MRI can be prescribed in patients with implanted cardiac devices (pacemaker, defibrillator) to optimize radiotherapy planning]. [MRI可用于植入心脏装置(起搏器、除颤器)的患者，以优化放疗计划]。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2020-05-19 DOI: 10.1016/j.canrad.2020.03.001

J. Bouter, J. Lacroix, J. Baud, J. Thariat

引用次数: 0

[Prostate cancer]. (前列腺癌)。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2020-04-01 DOI: 10.1097/ju.0000000000000856

P. Bey, V. Beckendorf, J. Stines

{"title":"[Prostate cancer].","authors":"P. Bey, V. Beckendorf, J. Stines","doi":"10.1097/ju.0000000000000856","DOIUrl":"https://doi.org/10.1097/ju.0000000000000856","url":null,"abstract":"Radiation therapy of prostate carcinoma with a curative intent implies to treat the whole prostate at high dose (at least 66 Gy). According to clinical stage, PSA level, Gleason's score, the clinical target volume may include seminal vesicles and less often pelvic lymph nodes. Microscopic extracapsular extension is found in 15 to 60% of T1-T2 operated on, specially in apex tumors. On contrary, cancers developing from the transitional zone may stay limited to the prostate even with a big volume and with a high PSA level. Zonal anatomy of the prostate identifies internal prostate, including the transitional zone (5% of the prostate in young people). External prostate includes central and peripheral zones. The inferior limit of the prostate is not lower than the inferior border of the pubic symphysis. Clinical and radiological examination: ultrasonography, nuclear magnetic resonance (NMR), CT-scan identify prognostic factors as tumor volume, capsule effraction, seminal vesicles invasion and lymph node extension. The identification of the clinical target volume is now done mainly by CT-Scan which identifies prostate and seminal vesicles. NMR could be helpful to identify more precisely prostate apex. The definition of margins around the clinical target volume has to take in account daily reproducibility and organ motion and of course the maximum tolerable dose for organs at risk.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":"36 1","pages":"560-70"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83615329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Basis and perspectives of artificial intelligence in radiation therapy]. [人工智能在放射治疗中的基础与前景]。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2019-12-01 DOI: 10.1016/j.canrad.2019.08.005

A. Burgun

引用次数: 3

[Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play]. [纳米颗粒在放射治疗中作为放射增敏剂的使用:研究现状]。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2019-12-01 DOI: 10.1016/j.canrad.2019.07.134

C. Verry, Erika Porcel, Cyrus Chargari, C. Rodriguez-Lafrasse, J. Balosso

引用次数: 13

[Solitary bone plasmocytoma: Experience from the radiotherapy department at Mohammed-V military teaching hospital in Rabat (Morocco)]. [孤立性骨浆细胞瘤:来自拉巴特(摩洛哥)穆罕默德五世军事教学医院放疗部的经验]。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2019-10-31 DOI: 10.1016/j.canrad.2019.06.013

K. Hadadi, M. Hommadi, M. Belemlih, N. Zaghba, Abdelhak Maghous, El-Amin Marnouch, K. A. Saghir, M. Elmarjany, H. Sifat, M. Oukabli, H. Mansouri

引用次数: 1

[Inter- and intrafraction imaging during stereotactic body radiation therapy: Which solutions for which tumours?] 立体定向全身放射治疗时的抽束间和抽束内成像:针对哪种肿瘤采用哪种解决方案?］

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2019-10-12 DOI: 10.1016/j.canrad.2019.09.001

D. Gensanne, A. Henni, Y. Lauzin, P. Clarisse, S. Thureau

引用次数: 0

DNA repair inhibitors to enhance radiotherapy: Progresses and limitations. DNA修复抑制剂增强放疗:进展和局限性。

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2019-10-12 DOI: 10.1016/j.canrad.2019.08.008

S. Ferreira, M. Dutreix

引用次数: 9

Illustration of a fatal radiation-induced lung aneurysm: Is central lung stereotactic radiotherapy to be banned? 致死性放射诱发肺动脉瘤:中央肺立体定向放疗是否应被禁止?

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique Pub Date : 2019-10-11 DOI: 10.1016/j.canrad.2019.05.016

B. Ledoux, M. Dupont, F. Duplaquet, L. Pirard, S. Ocak, M. Wanet, V. Remouchamps

引用次数: 5